These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 8372596)

  • 21. Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone.
    Eagleson CA; Gingrich MB; Pastor CL; Arora TK; Burt CM; Evans WS; Marshall JC
    J Clin Endocrinol Metab; 2000 Nov; 85(11):4047-52. PubMed ID: 11095431
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Levels of follicle-stimulating hormone, luteinizing hormone, oestradiol-17 beta and progesterone, and follicular growth in the pseudopregnant rat.
    Welschen R; Osman P; Dullaart J; de Greef WJ; Uilenbroek JT; de Jong FH
    J Endocrinol; 1975 Jan; 64(1):37-47. PubMed ID: 1167896
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pituitary responsiveness to gonadotrophin-releasing hormone agonist stimulation: a dose-response comparison of luteinizing hormone/follicle-stimulating hormone secretion in women with polycystic ovary syndrome and normal women.
    Cheung AP; Chang RJ
    Hum Reprod; 1995 May; 10(5):1054-9. PubMed ID: 7657740
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Purified follicle-stimulating hormone in polycystic ovary syndrome: slow administration is safer and more effective.
    Buvat J; Buvat-Herbaut M; Marcolin G; Dehaene JL; Verbecq P; Renouard O
    Fertil Steril; 1989 Oct; 52(4):553-9. PubMed ID: 2509248
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of low dose human chorionic gonadotropin on follicular response and oocyte maturation in PCOS patients undergoing IVF cycles: a randomized clinical trial of efficacy and safety.
    Ashrafi M; Kiani K; Ghasemi A; Rastegar F; Nabavi M
    Arch Gynecol Obstet; 2011 Dec; 284(6):1431-8. PubMed ID: 21210134
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevalence of diminished ovarian reserve in Chinese women with polycystic ovary syndrome and sensitive diagnostic parameters.
    Jin J; Ruan X; Hua L; Tian X; Li Y; Wang L; Mueck AO
    Gynecol Endocrinol; 2017 Sep; 33(9):694-697. PubMed ID: 28412857
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sequential step-up and step-down dose regimen: an alternative method for ovulation induction with follicle-stimulating hormone in polycystic ovarian syndrome.
    Hugues JN; Cédrin-Durnerin I; Avril C; Bulwa S; Hervé F; Uzan M
    Hum Reprod; 1996 Dec; 11(12):2581-4. PubMed ID: 9021354
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Endocrinological environment with regard to the number of microcysts in patients with polycystic ovary syndrome.
    Yoshino K; Takahashi K; Eda Y; Okada S; Kitao M
    Hum Reprod; 1992 Oct; 7(9):1201-4. PubMed ID: 1478997
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum inhibin levels in polycystic ovary syndrome: basal levels and response to luteinizing hormone-releasing hormone agonist and exogenous gonadotropin administration.
    Buckler HM; McLachlan RI; MacLachlan VB; Healy DL; Burger HG
    J Clin Endocrinol Metab; 1988 Apr; 66(4):798-803. PubMed ID: 3126215
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ovarian age-related responsiveness to human chorionic gonadotropin in women with polycystic ovary syndrome.
    Piltonen T; Koivunen R; Perheentupa A; Morin-Papunen L; Ruokonen A; Tapanainen JS
    J Clin Endocrinol Metab; 2004 Aug; 89(8):3769-75. PubMed ID: 15292303
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low-dose exogenous FSH initiated during the early, mid or late follicular phase can induce multiple dominant follicle development.
    Hohmann FP; Laven JS; de Jong FH; Eijkemans MJ; Fauser BC
    Hum Reprod; 2001 May; 16(5):846-54. PubMed ID: 11331627
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low levels of follicle-stimulating hormone receptor-activation inhibitors in serum and follicular fluid from normal controls and anovulatory patients with or without polycystic ovary syndrome.
    Schipper I; Rommerts FF; Ten Hacken PM; Fauser BC
    J Clin Endocrinol Metab; 1997 May; 82(5):1325-31. PubMed ID: 9141511
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Blood flow changes in the ovarian and uterine arteries in women with polycystic ovary syndrome who respond to clomiphene citrate: correlation with serum hormone concentrations.
    Zaidi J; Jacobs H; Campbell S; Tan SL
    Ultrasound Obstet Gynecol; 1998 Sep; 12(3):188-96. PubMed ID: 9793191
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Effect of luteinizing hormone vs follicular stimulating hormone ratio on anti-Müllerian hormone secretion and folliculogenesis in patients with polycystic ovarian syndrome].
    Li Y; Wei LN; Xiong YL; Liang XY
    Zhonghua Fu Chan Ke Za Zhi; 2010 Aug; 45(8):567-70. PubMed ID: 21029609
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Polycystic ovary syndrome: low-dose follicle stimulating hormone administration is a safe stimulation regimen even in previous hyper-responsive patients.
    Dale PO; Tanbo T; Haug E; Abyholm T
    Hum Reprod; 1992 Sep; 7(8):1085-9. PubMed ID: 1400931
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Women with oligo-/amenorrhoea and polycystic ovaries have identical responses to GnRH stimulation regardless of their androgen status: comparison of the Rotterdam and Androgen Excess Society diagnostic criteria.
    Lewandowski KC; Cajdler-Luba A; Bieńkiewicz M; Lewiński A
    Neuro Endocrinol Lett; 2011; 32(6):847-56. PubMed ID: 22286802
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is the inappropriate gonadotropin secretion of patients with polycystic ovary syndrome similar to that of patients with adult-onset congenital adrenal hyperplasia?
    Levin JH; Carmina E; Lobo RA
    Fertil Steril; 1991 Oct; 56(4):635-40. PubMed ID: 1915936
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Follicular arrest in polycystic ovary syndrome is associated with deficient inhibin A and B biosynthesis.
    Welt CK; Taylor AE; Fox J; Messerlian GM; Adams JM; Schneyer AL
    J Clin Endocrinol Metab; 2005 Oct; 90(10):5582-7. PubMed ID: 16030174
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recombinant human luteinizing hormone (LH) to support recombinant human follicle-stimulating hormone (FSH)-induced follicular development in LH- and FSH-deficient anovulatory women: a dose-finding study. The European Recombinant Human LH Study Group.
    J Clin Endocrinol Metab; 1998 May; 83(5):1507-14. PubMed ID: 9589647
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A pharmacodynamic comparison of human urinary follicle-stimulating hormone and human menopausal gonadotropin in normal women and polycystic ovary syndrome.
    Anderson RE; Cragun JM; Chang RJ; Stanczyk FZ; Lobo RA
    Fertil Steril; 1989 Aug; 52(2):216-20. PubMed ID: 2502437
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.